| Literature DB >> 30167433 |
Murugesan Harishankar1, Paramasivam Selvaraj1, Ramalingam Bethunaickan1.
Abstract
Tuberculosis (TB) is still remains the major threat for human health worldwide. Several case-control, candidate-gene, family studies and genome-wide association studies (GWAS) suggested the association of host genetic factors to TB susceptibility or resistance in various ethnic populations. Moreover, these factors modulate the host immune responses to tuberculosis. Studies have reported genetic markers to predict TB development in human leukocyte antigen (HLA) and non-HLA genes like killer immunoglobulin-like receptor (KIR), toll-like receptors (TLRs), cytokine/chemokines and their receptors, vitamin D receptor (VDR) and SLC11A1 etc. Highly polymorphic HLA loci may influence antigen presentation specificities by modifying peptide binding motifs. The recent meta-analysis studies revealed the association of several HLA alleles in particular class II HLA-DRB1 with TB susceptibility and valuable marker for disease development especially in Asian populations. Case-control studies have found the association of HLA-DR2 in some populations, but not in other populations, this could be due to an ethnic specific association of gene variants. Recently, GWAS conducted in case-control and family based studies in Russia, Chinese Han, Morocco, Uganda and Tanzania revealed the association of genes such as ASAP1, Alkylglycerol monooxygenase (AGMO), Forkhead BoxP1 (FOXP1), C-terminal domain phosphatase 1 (UBLCP1) and intergenic SNP rs932347C/T with TB. Whereas, SNP rs10956514A/G were not associated with TB in western Chinese Han and Tibetan population. In this review, we summarize the recent findings of genetic variants with susceptibility/resistance to TB.Entities:
Keywords: HLA genes; Mycobacterium tuberculosis; Non HLA genes; cytokine and chemokine polymorphisms; genetic polymprhisms in TB; host genetics
Year: 2018 PMID: 30167433 PMCID: PMC6106802 DOI: 10.3389/fmed.2018.00213
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Association between HLA and TB in different ethnic population.
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
| ||||
| Asian/India | HLA-DR2 | Susceptibility | 287 | 143 | ( |
| HLAB*57 | Protective in female HIV patients | 682 | 238 | ( | |
| HLA-DRB1*1501 and DQB1*0601 | Susceptibility | 87 | 126 | ( | |
| DPB1*04 | Protective | ||||
| DRB1*1501 | Susceptibility | 46 | 20 | ( | |
| DRB1*1501-DRB5*0101-DQA1*0103-DQB1*0601(Haplotype) | Susceptibility | ||||
| HLA-DR2 | Susceptibility | 289 | 153 | ( | |
| DRB1*1501 and DRB1*1502 | |||||
| A2 | Susceptibility | 329 | 153 | ( | |
| B18 | Protective | ||||
| HLA-DRB1*14, DQB1*0503 and DQB1*0502 | Susceptibility | – | – | ( | |
| DRw6 | Protective | 109 | 124 | ( | |
| DR2 | Susceptibility | – | 25 families | ( | |
| A1- like supertype | Protective | 289 | 235 | ( | |
| A3- like supertype | Susceptibility | ||||
| HLA-DRB1*15 | Susceptibility | 178 | 210 | ( | |
| A*24-B*40-DRB1*15 | |||||
| HLA-DRB1*16 | Protection | ||||
| A*02-B*40-DRB1*16 and A*02-B40-DRB1*03 | |||||
| Asian/India | HLA-DR2 DQ1 | Susceptibility | 122 | 209 | ( |
| DRB1*1501(DR2) | Susceptibility (inverse correlation to lymphocyte proliferation response) | 36 | 72 | ( | |
| Downregulation of perforin positive CTL and NK cells | ( | ||||
| Haplotypes | Susceptibility to TB in HIV | ( | |||
| HLA-DRB1*1502-DPB1*0201 | |||||
| HLA-DQB1*0601-DPB1*0201 | |||||
| HLA-DRB1*1502-DQB1*0601-DPB1*0201 | |||||
| HLA-A11,1101 | Protective to HIV and HIV-TB | ( | |||
| HLA-B40, 4006 | Susceptibility to HIV and HIV-TB | ||||
| HLA-DR2 | Susceptibility to HIV and HIV-TB | ||||
| HLA-DRB1*1502 | Susceptibility to HIV-TB | ( | |||
| HLA-DQB1*050301 | Susceptibility to HIV and HIV-TB | ||||
| HLA-DPB1*1501 | Protective to TB and HIV-TB | ||||
| HLA-DRB1*13, HLA-DRB5 and HLA-DQB1*06 | Susceptibility to TB in HIV | 50 | 50 | ( | |
| HLA DQB1*02 | Protective to TB in HIV | ||||
| HLA-B*15 | Susceptibity to TB in HIV | ||||
| HLA-B*51 | Protective to TB in HIV | ||||
| Asian/China | HLA-DR,DQ | Susceptibility to bone TB | 88 | 86 | ( |
| HLA-DRB1 * 15 HLA-DRB1 * 11 | SusceptibilityProtective | 90 | 74 | ( | |
| DRB1 * 09 | Susceptibility to PTB with type2 diabetes mellitus | 46 | 123 | ( | |
| DQB1 * 05 | Protective to PTB with type2 diabetes mellitus | ||||
| DR1 and DR13.3 | Protective to PTB | 101 | 110 | ( | |
| HLA-DR and DQ | Susceptibility | 146 | 146 | ( | |
| HLA-DRB | Susceptibility | 62 | 97 | ( | |
| HLA-DRB1 | Susceptibility | 105 | 80 | ||
| HLA-DRB1 | Susceptibility | 231 | 226 | ( | |
| HLA-DRB1, DQA1 and DQB1 | Susceptibility | 189 | 176 | ( | |
| HLA-DRB1*04 and HLA-DQB1*0201 | Susceptibility | 230 | 231 | ( | |
| Asian/Korea | DRB1*0803 and DQB1*0601 | Susceptibility | 200 | 160 | ( |
| Asian/Combodia | HLA-DQB1*0503 | Susceptibility | 88 | 126 | ( |
| African/ SouthAfrica | DRB1*1302 | Susceptibility | 117 | 95 | ( |
| DRB1*1302- DQB1*0602/3(Haplotype) DQB1*0301-0304(Phenotype) DQB1*0301-0304/DRB1*1101-1121(Haplotype) DRB1*1101-1121-DQB1*05(Haplotype) | |||||
| African/Uganda | HLA-DQB1*03:03 | 42 | 43 | ( | |
| Caucasian/ Mexico | DQA1*0101,DQB1*0501 and DRB1*1501 | Susceptibility | 95 | 50 | ( |
| DQB1*0402, DR4 and DR8 | Protection | ||||
| Caucasian/Iran | HLA-DRB1*07 and HLA-DQA1*0101 | Susceptibility | 100 | 40 | ( |
| HLA-DQA1*0301 and 0501 | Protective | ||||
| A26 and B27 B17 and DR14 | Protective Susceptibility | 108 | 44 | ( | |
| Caucasian/Syria | DRB1*04 DRB1*11 | Susceptibility Protective | 209 | 147 | ( |
| Caucasian/ Portugal | HLA-DRB1*14 | Susceptibility | 82 | 92 | ( |
| Caucasian/Greek | HLA-A R114and HLA-DRβN37(Aminoacid poly) | Susceptibility | 46 | 86 | ( |
| HLA-A S77 | Protection | ||||
| Caucasian/Brazil | HLA-A*02 and HLA-B*18 | Protection | 224 | 112 | ( |
| Canadian/Canada | B8 HLA-A*03 and HLA-DQB1*05:03 | Susceptibility Susceptibility | 543 – | 46 – | ( |
| Black American/United states | B5 and DR5 DR6 | Susceptibility Protection | 54 | 72 | ( |
| Italian/Italy | DR4 or along with B14 A2+,B14-,DR4- | Susceptibility Protection | 1089 | 122 | ( |
| Indonesian/ Indonesia | DR2 and DQw1 DQw3 | Susceptibility Protection | 64 | 101 | ( |
| Polish/Poland | DRB1*13 DRB1*16 DRB1*05DRB1*1601-DQB1*0502, DRB1*04-DQB1*03 and DRB1*14-DQB1*05 DRB1*11-DQB1*03 | ProtectionSusceptibilitySusceptibilitySusceptibility | 58 58125 | 313861 | ( |
| Thai/Thailand | HLA-DQB1*0502HLA-DQA1*0601 and DQB1*0301 HLA-DRB1*09:01 and HLA-DQB1*03:03 | SusceptibilityProtectionSusceptibility | 160 836 | 82 682 | ( |
| Soviet Union (six Ethnic groups) / Russia | DR2 DR3 | Susceptibility Protection | 984 | 643 | ( |
| Iraqi Arab | HLA-B18 and HLA-DR1HLA-B5 and HLA-DR8 | Susceptibility Protection | 40 | 105 | ( |
Association of DC-SIGN polymorphisms among different ethnic populations.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
|
| |||||
| −871(A/G)−336(A/G) | South African | −871G −336A | Protection | 360 | 351 | ( |
| −939(G/A) | Indonesian Vietnamese | GG vs. GA+AA | Protection No association | ( | ||
| −336(A/G) | South Indian | −336GG | Susceptibility to PTB in HIV | 157 | 107 | ( |
| African | −336G | Protection | 914 | 1,262 | ( | |
| Asian | −336GG | Susceptibility | 3,610 | 3,539 | ( | |
| Asian | −336GG | Susceptibility | 3,088 | 3,114 | ( | |
| −871G | Protection | |||||
| −336(A/G) | Spanish | No association | 299 | 110 | ( | |
| DC-SIGNR VNTR | Iranian | No association | 161 | 171 | ( | |
| −336(A/G)139(A/G) | West African | No association | 347 | 321 | ( | |
| −336(A/G) | Chinese | No association | 2614 | 2598 | ( | |
DC-SIGN, Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin.
Association of MBL gene polymorphisms in different ethnic populations to TB.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
|
| |||||
| Exon1 (Codon 52, 54 and 57) | South Indian | Mutant homozygous | Susceptibility | 109 | 202 | ( |
| Exon 1, codon-52 | Chinese | Heterozygous | Susceptibility | 198 | 125 | ( |
| −221Y/X | South Indian | O/O genotype YA/YA diplotype | Susceptibility Susceptibility to TB in HIV | 146 | 148 | ( |
| Codon 54, 57 | Turkish | AB genotype | Protection | 99 | 27 | ( |
| Exon 1 −550(H/L) −221(X/Y) +4(P/Q) | Italian | HYA-HYA (Haplotype) LYB-LYD (Haplotype) | Protection Susceptibility | 288 | 277 | ( |
| Exon 1 Codon54(A/B) | Indian | B' allele | Protection | 392 | 286 | ( |
| −221(Y/X) Exon 1 Codon57(A/C) | Brazilian | X/Y genotype ‘O' allele ‘C' allele and ‘AC' genotype | Susceptibility Susceptibility Susceptibility | 148 | 155 | ( |
| Exon1 codon 54(A/B) +4 (P/Q) | Chinese | 54 ‘B' allele +4 ‘P/Q' | Susceptibility No association | 1190 | 1106 | ( |
| rs7096206(C/G) rs6695096(T/C) rs2273346(T/C) | Chinese | ‘CG' genotype ‘TC' genotype ‘TC' genotype | Susceptibility Susceptibility Susceptibility | 216 419 | 205 503 | ( |
| −550 (H/L) Codon 52 (A/B) +4 (P/Q) −221 (X/Y) | Chinese | HL genotype HPYA, LPXA, LQYA & LPYB (Haplotypes) | Protection Susceptibility | 453 | 151 | ( |
| Exon 1 (Codon 54 and 57) | Turkish | No association | 50 | 50 | ( | |
| Exon1 Codon 52,54 and 57 | West Africa | No association | 2346 | 2010 | ( | |
MBL, Mannose binding lectin.
Chemokine gene polymorphisms in various ethnic populations.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
|
| |||||
| Whites/USA African American Paraguayan South Indian Gambian | −251“A”−251“T” | Susceptibility Protection No association | 107 167 − 124 320 | 106 180 96 127 360 | ( | |
| Mexican | “GG” and “AG” | Susceptibility | 518 | 435 | ( | |
| Korean | 162 | 129 | ||||
| Brazilian | No association | – | 627 | ( | ||
| Morroccan | −2518GG | Protection | – | – | ( | |
| −2362C | West African | 2362C | Protection | 2300 | 2000 | ( |
| Chinese | A-C-T, G-C-C (Haplotype) Diplotypes (-403&In1.1) GA/TT; GG/TC | Susceptibility | 465 | 412 | ( | |
| Tunisian | −28GG G-G, A-C (Haplotypes) AG/GC (diplotypes) Of-403&-28 | 150 | 168 | ( | ||
| South Indian | A-C-C (haplotype) G/A-T/C (diplotype) | Protection | 213 | 212 | ( | |
| North Indian | −403G/A | Susceptibility | 215 | 215 | ( | |
| Sudanese | −28G | 206 | 191 | ( | ||
| Mexican Korean | No association | 518 | 435 | ( | ||
| Brazilian | rs1634514T rs1719144A | Susceptibility | – | 627 | ( | |
| Brazilian | rs2015086C rs2015070A rs14304A | Protective | – | 627 | ( | |
| Chinese | Susceptibility No association | 176 | 240 | ( | ||